All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
2023-02-16T10:45:15.000Z

How robust is POD24 as a predictor of survival in indolent lymphomas?

Feb 16, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Narendranath Epperla, Ohio State University, Columbus, US. We asked, How robust is POD24 (progression of disease within 24 months) as a predictor of survival in indolent lymphomas?

How robust is POD24 as a predictor of survival in indolent lymphomas?

Epperla begins by discussing the prognostic relevance of POD24, specifically in a multicenter U.S. based cohort study of patients with marginal zone lymphoma. He concludes that patients with POD24 had poorer outcomes compared with non-POD24 patients, outlining POD24 as an important clinical predictor of high-risk patients with follicular lymphoma or marginal zone lymphoma.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox